Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Aratana Therapeutics provides business update, expects ENTYCE to be commercially available by late-2017 (8.03)<p>In connection with the 2017 North American Veterinary Conference in Orlando, Florida, on February 6, 2017, Aratana Therapeutics provided certain business updates.</p><ul><li>The Company now anticipates that ENTYCE (capromorelin oral solution) will be commercially available by late-2017. On February 2, 2017, the Company received a response from the U.S. Food and Drug Administration's Center for Veterinary Medicine in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at commercial scale. The CVM has requested additional information regarding the proposed transfer in order to complete the supplemental application, and the Company intends to work with the CVM to address its request.</li><li>With the expected later commercial launch of ENTYCE, the Company intends to continue to focus its commercial resources on NOCITA (bupivacaine liposome injectable suspension), a local post-operative analgesia for cranial cruciate ligament surgery in dogs, which became commercially available in the late fall of 2016. The Company is focusing on gaining access to the several hundred surgeons who frequently perform these procedures. This effort has required, and the Company expects it will continue to require, significant effort by its sales force given the longer sales cycle than what the Company would expect with a general practice product. The Company is also conducting additional clinical work in other surgical procedures to potentially expand the label for NOCITA in dogs.</li></ul></td> </tr></table>"